Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases

Journal of Oncology Pharmacy Practice

Volumn 20, Issue 2, 2014, Pages 120-129

  Eckmann, Karen ^a   Michaud, Laura B ^a   Rivera, Edgardo ^a,b   Madden, Timothy L ^a   Esparza Guerra, Laura ^a,c   Kawedia, Jitesh ^a   Booser, Daniel J ^a   Green, Marjorie C ^a   Hortobagyi, Gabriel N ^a   Valero, Vicente ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Banner MD Anderson Cancer Center   (United States)

^c US Oncology   (United States)

Author keywords

chemotherapy; Docetaxel; hepatic dysfunction; liver impairment; metastatic breast cancer; taxanes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DOCETAXEL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CHOLESTASIS; DISEASE COURSE; DRUG DOSE INCREASE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; RASH; SEVERE HEPATIC IMPAIRMENT; VOMITING;

CHEMOTHERAPY; DOCETAXEL; HEPATIC DYSFUNCTION; LIVER IMPAIRMENT; METASTATIC BREAST CANCER; TAXANES;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; LIVER; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; TAXOIDS;

EID: 84898948465     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155213480536     Document Type: Article

References (25)

1. Miksad R, Hanto D, Timmerman RD, et al Diseases of the breast. 4 th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2009, pp. 1030-1037. Harris JR Lippman ME Morrow M, ed. Philadelphia, PA: Lippincott Williams & Wilkins ; 2009: 1030-1037.
2. Cheidozi LC. Prognostic significance of exclusive skeletal metastases in stage IV primary carcinoma of the breast. Surg Gynecol Obstet. 1988 ; 167: 303-306
3. Niikura N, Liu J, Hayashi N, et al. Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. Oncologist. 2011 ; 16: 155-164
4. Er O, Frye DK, Kau SW, et al. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J. 2008 ; 14: 62-68
5. Pentheroudakis G, Fountzilas G, Bafaloukos D, et al. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management, and outcome characteristics of 500 women. Breast Cancer Res Treat. 2006 ; 97: 237-244 (Pubitemid 43945754)
6. Holmes FA, Valero V, Theriault RL, et al. Phase II trial of Taxol in metastatic breast cancer refractory to multiple prior treatments (abstract 178). Proc Am Soc Clin Oncol. 1993 ; 12: 94-94
7. Reichman BS, Seidman AD, Crown JP, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 1993 ; 11: 1943-1951 (Pubitemid 23304620)
8. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995 ; 13: 2886-2894
9. Fumoleau P, Chevallier B, Kerbrat P, et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Ann Oncol. 1996 ; 7: 165-171 (Pubitemid 26094881)
10. Montero A, Fosella F, Hortobagyi G, et al. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005 ; 6: 229-239 (Pubitemid 40450714)
11. Valero V, Jones SE, Von Hoff DD, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998 ; 16: 3362-3368 (Pubitemid 28481633)
12. Venook AP, Egorin M, Brown TD, et al. Paclitaxel (Taxol) in patient with liver dysfunction (CALGB 9264) (abstract 350). Proc Am Soc Clin Oncol. 1994 ; 13: 139-139
13. Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998 ; 16: 1811-1819
14. Paclitaxel (package insert). Princeton, NJ: Bristol-Myers Squibb Co ; 2011 :
15. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998 ; 16: 187-196 (Pubitemid 28041598)
16. Sanofi-Aventis. Taxotere® (package insert). Bridgewater, NJ: Sanofi-Aventis, 2010.
17. Minami H, Kawada K, Sasaki Y, et al. Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Sci. 2009 ; 100: 144-149
18. Sonnichsen DA, Hurwitz CA, Pratt CB, et al. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol. 1994 ; 12: 532-538 (Pubitemid 24079895)
19. Huizing MT, Vermorken JB, Rosing H, et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol. 1995 ; 6: 699-704
20. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995 ; 13: 180-190
21. Bruno R, Vivier N, Veyrat-Follet C, et al. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs. 2001 ; 19: 163-169 (Pubitemid 32423721)
22. Hoe AL, Royle GT, Taylor I. Breast liver metastases - incidence, diagnosis, and outcome. J R Soc Med. 1991 ; 84: 714-716
23. Wyld L, Gutteridge E, Pinder SE, et al. Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer. 2003 ; 89: 284-290 (Pubitemid 36976317)
24. Kurnik D, Wood AJJ, Wilkinson GR. The erythromycin breath test reflects p-glycoprotein function independently of cytochrome p450 3A activity. Clin Pharmacol Ther. 2006 ; 80: 228-234 (Pubitemid 44301092)
25. Collins JM. Cytochrome P-450 and other determinants of pharmacokinetics, toxicity, and efficacy in humans. Clin Cancer Res. 2000 ; 6: 1203-1204 (Pubitemid 30226199)